Fig. 2.

STMN2 and UNC13A RNAs are mis-processed in post-mortem brain of approximately half of patients with Alzheimer’s disease. a Table depicting the detection of STMN2 (red) or UNC13A (purple) cryptic exons in the amygdala of controls and Alzheimer’s disease patients with (+) and without (−) phosphorylated TDP-43 pathology. b–e Levels of truncated STMN2 RNA (red) or UNC13A cryptic exon (purple) measured by qRT-PCR in post-mortem amygdala (b, d) or entorhinal cortex (c, e) from patients with Alzheimer’s disease (AD) associated ( +) or not (−) with accumulation of phosphorylated TDP-43. Normal distribution of data was tested using D’Agostino & Pearson test and a one-way ANOVA followed by a Sidak’s multiple comparisons post-hoc test (parametric), or a Kruskal–Wallis, followed by a Dunn’s Multiple comparisons post-hoc test (non-parametric) were performed accordingly. f Log–log plot of STMN2 and UNC13A cryptic exon levels detected in the amygdala of Alzheimer’s disease patients. Correlation was determined using spearman rank coefficient and curve fitting with non-linear regression. g RT-PCR confirming the detection of STMN2 and UNC13A cryptic exons in a subset of the patients with Alzheimer’s disease associated with phosphorylated TDP-43 (pTDP-43) pathology